HK2 and hepatocellular carcinoma: Due to the importance of glycolysis in the progression of liver cancer, the targeting of key rate-limiting enzymes in the glycolysis pathway (eg. hexokinase 2, phosphofructokinase 1 or type M2 and pyruvate kinase) is a novel approach for HCC treatment.